ATE555215T1 - Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert - Google Patents

Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert

Info

Publication number
ATE555215T1
ATE555215T1 AT06774185T AT06774185T ATE555215T1 AT E555215 T1 ATE555215 T1 AT E555215T1 AT 06774185 T AT06774185 T AT 06774185T AT 06774185 T AT06774185 T AT 06774185T AT E555215 T1 ATE555215 T1 AT E555215T1
Authority
AT
Austria
Prior art keywords
correlates
molecular
represent
result
neoplastic disease
Prior art date
Application number
AT06774185T
Other languages
English (en)
Inventor
David Hoon
Joseph Kim
Original Assignee
Wayne John Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst filed Critical Wayne John Cancer Inst
Application granted granted Critical
Publication of ATE555215T1 publication Critical patent/ATE555215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06774185T 2005-06-27 2006-06-27 Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert ATE555215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69438305P 2005-06-27 2005-06-27
PCT/US2006/025165 WO2007002746A2 (en) 2005-06-27 2006-06-27 Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome

Publications (1)

Publication Number Publication Date
ATE555215T1 true ATE555215T1 (de) 2012-05-15

Family

ID=37596015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06774185T ATE555215T1 (de) 2005-06-27 2006-06-27 Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert

Country Status (7)

Country Link
US (1) US20070031867A1 (de)
EP (1) EP1898803B1 (de)
JP (1) JP2009501004A (de)
AT (1) ATE555215T1 (de)
AU (1) AU2006261671A1 (de)
CA (1) CA2617755A1 (de)
WO (1) WO2007002746A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065626A1 (en) * 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
JP5652809B2 (ja) 2009-03-02 2015-01-14 株式会社ルネッサンス・エナジー・インベストメント 癌組織由来細胞塊およびその調製法
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
US20130012404A1 (en) * 2010-01-19 2013-01-10 Osaka Prefectural Hospital Organization Culture method, evaluation method and storage method for cancer-tissue-derived cell mass or aggregated cancer cell mass
GB201100150D0 (en) * 2011-01-06 2011-02-23 Epistem Ltd Mutational analysis
EP3158085B1 (de) 2014-06-18 2020-12-02 Clear Gene, Inc. Verfahren zur schnellanalyse von biologischen markern
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
AU2016369603A1 (en) 2015-12-18 2018-07-05 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020235A1 (en) * 1992-04-01 1993-10-14 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
AU5587998A (en) * 1996-11-15 1998-06-03 Cornell Research Foundation Inc. Activated ras interaction assay

Also Published As

Publication number Publication date
JP2009501004A (ja) 2009-01-15
CA2617755A1 (en) 2007-01-04
AU2006261671A1 (en) 2007-01-04
EP1898803B1 (de) 2012-04-25
WO2007002746A3 (en) 2009-04-30
EP1898803A4 (de) 2010-01-20
US20070031867A1 (en) 2007-02-08
EP1898803A2 (de) 2008-03-19
WO2007002746A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE555215T1 (de) Molekulare/genetische aberrationen in chirurgischen rändern von pankreaskrebsresektionen stellen eine neoplastische erkrankung dar, die mit dem resultat korreliert
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1114661T1 (el) Ταυτοποιηση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
CR9512A (es) Metodos para el tratamiento de tumores de cerebro con anticuerpos
DE602006019128D1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
BRPI0513896A (pt) método para a discriminação entre tecido saudável e de tumor
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
EA201200101A1 (ru) Способ прогнозирования эффективности лекарственных соединений для пациента
WO2005123942A3 (en) Analysis of methylated nucleic acid
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
EA200801853A1 (ru) Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
Goss et al. Targeting the Wnt pathway in cancer
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
DE602005018398D1 (de) Identifizierung pdgfr-alpha exprimierender nsclc (non-small cell lung carcinoma)-tumoren
ATE534902T1 (de) Replikationsproteinn ciz1
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas